Contradictory Immune Response in Post Liver Transplantation Hepatitis B and C

Table 1

Recent post-OLT HBV prophylaxis with nucleos(t)ide analogue and/or HBIG combination.

	HBV-DNA recurrence (%)	Followup (months)	Reference number	Reported year
Lamivudine + HBIG
HBIG IV 10000 IU/month	0	13	[93]	1998
HBIG IV to maintain HBsAb >200 IU/L	9.5	21 (2.4–49.1)	[96]	2001
HBIG to maintain HBsAb >70 IU/L	0	16 (9–22)	[97]	2004
HBIG IV to maintain HBsAb >10 IU/L	0	30 (7–73)	[6]	2007
Short course (1 month) HBIG	7	18	[98]	2003
Entecavir + HBIG
HBIG; IM to maintain HBsAb >100 IU/L	0	41.2 (33–54)	[107]	2012
One year HBIG IM; 2000 IU/month; Lamivudine + adefovir or tenofovir, tenofovir, entecavir	0	24 (6–40) post HBIG withdrawal	[106]	2012
One year HBIG IV; dose not specified	3.8	24	[105]	2013
HBIG free with newer nucleos(t)ide analogues regimen
Lamivudine + adefovir; (no HBIG when HBV-DNA below )	0	22 (10–58)	[103]	2013
Entecavir, lamivudine + adefovir, tenofovir, entecavir + tenofovir; (no HBIG when HBV-DNA below )	8 (5/6 withdrawn NAs)	21 (1–83)	[110]	2013

OLT; orthotopic liver transplantation, HBV: hepatitis B virus, HBIG; hepatitis B immunoglobulin, HBV-DNA: hepatitis B virus DNA, IV: intravenous administration, IM: intramuscular administration, IU: international unit, HBsAb: anti-hepatitis B s antibody, and NAs: nucleos(t)ide analogues.